Background: This study aimed to evaluate the relationship between systolic blood pressures (SBPs) within 10 hours after intravenous recombinant tissue plasminogen activator (rtPA) treatment and early neurological outcomes in geriatric and nongeriatric patients with acute ischemic stroke (AIS). Methods: This was a retrospective observational study of patients with AIS who received intravenous rtPA between January 2010 and May 2015. Clinical factors were compared between geriatric and nongeriatric patients. SBPs at the time of rtPA bolus and every hour thereafter were collected. The primary outcome was major neurological improvement (MNI) at 24 hours after thrombolysis. Results: Serial measures of SBP revealed different 10-hour courses betwee...
BACKGROUND: Intravenously administered tissue plasminogen activator (IV tPA) remains the only approv...
Background: To investigate the influence of the initial readings of blood pressure (BP) components o...
<div><p>Objectives</p><p>The benefit of intravenous recombinant tissue plasminogen activator (rt-PA)...
Transiently high blood pressure (BP) is common during the first 24 to 48 hour after the onset of st...
Background: Outcomes are worse in patients who underwent thrombolysis for acuteischemic stroke (AIS)...
The goal of this study was to examine the relationship between BP variations and neurological defici...
The goal of this study was to examine the relationship between BP variations and neurological defici...
Background: Early neurological improvement has been observed in patients with stroke receiving treat...
Increased blood pressure (BP) management following acute ischemic stroke (AIS) remains controversial...
Background and Purpose: In thrombolysis-eligible patients with acute ischemic stroke, th...
Background and Purpose: The optimal management of blood pressure (BP) in acute stroke remains unclea...
AbstractBackgroundEarly neurological improvement has been observed in patients with stroke receiving...
Background: Intravenous thrombolysis is beneficial in, even very elderly, acute ischemic stroke pat...
Copyright © 2013 L. Bentsen et al. This is an open access article distributed under the Creative Com...
BACKGROUND: The benefit of intravenous tissue plasminogen activator (tPA) given within 3 h of acute ...
BACKGROUND: Intravenously administered tissue plasminogen activator (IV tPA) remains the only approv...
Background: To investigate the influence of the initial readings of blood pressure (BP) components o...
<div><p>Objectives</p><p>The benefit of intravenous recombinant tissue plasminogen activator (rt-PA)...
Transiently high blood pressure (BP) is common during the first 24 to 48 hour after the onset of st...
Background: Outcomes are worse in patients who underwent thrombolysis for acuteischemic stroke (AIS)...
The goal of this study was to examine the relationship between BP variations and neurological defici...
The goal of this study was to examine the relationship between BP variations and neurological defici...
Background: Early neurological improvement has been observed in patients with stroke receiving treat...
Increased blood pressure (BP) management following acute ischemic stroke (AIS) remains controversial...
Background and Purpose: In thrombolysis-eligible patients with acute ischemic stroke, th...
Background and Purpose: The optimal management of blood pressure (BP) in acute stroke remains unclea...
AbstractBackgroundEarly neurological improvement has been observed in patients with stroke receiving...
Background: Intravenous thrombolysis is beneficial in, even very elderly, acute ischemic stroke pat...
Copyright © 2013 L. Bentsen et al. This is an open access article distributed under the Creative Com...
BACKGROUND: The benefit of intravenous tissue plasminogen activator (tPA) given within 3 h of acute ...
BACKGROUND: Intravenously administered tissue plasminogen activator (IV tPA) remains the only approv...
Background: To investigate the influence of the initial readings of blood pressure (BP) components o...
<div><p>Objectives</p><p>The benefit of intravenous recombinant tissue plasminogen activator (rt-PA)...